indapamide has been researched along with Recrudescence in 9 studies
Indapamide: A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.
indapamide : A sulfonamide formed by condensation of the carboxylic group of 4-chloro-3-sulfamoylbenzoic acid with the amino group of 2-methyl-2,3-dihydro-1H-indol-1-amine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "PROGRESS (Perindopril Protection Against Recurrent Stroke Study) is a double-blind, placebo-controlled, randomized trial being conducted in 172 centres in 10 countries (Australia, Belgium, China, France, Italy, Ireland, Japan, New Zealand, Sweden, and the United Kingdom)." | 9.09 | PROGRESS (Perindopril Protection Against Recurrent Stroke Study): regional characteristics of the study population at baseline. PROGRESS Management Committee. ( Chalmers, J; MacMahon, S; Neal, B, 2000) |
| "Analyses of the risks of stroke were conducted for subjects with and without diabetes, participating in a randomized, double-blind, placebo-controlled trial of a perindopril-based blood pressure lowering regimen in 6105 people with prior stroke or transient ischaemic attack (TIA), followed for a median of 3." | 5.11 | Reductions in the risks of recurrent stroke in patients with and without diabetes: the PROGRESS Trial. ( Berthet, K; Bousser, MG; Chalmers, JP; Colman, SA; MacMahon, SW; Neal, BC; Woodward, M, 2004) |
| "PROGRESS (Perindopril Protection Against Recurrent Stroke Study) is a double-blind, placebo-controlled, randomized trial being conducted in 172 centres in 10 countries (Australia, Belgium, China, France, Italy, Ireland, Japan, New Zealand, Sweden, and the United Kingdom)." | 5.09 | PROGRESS (Perindopril Protection Against Recurrent Stroke Study): regional characteristics of the study population at baseline. PROGRESS Management Committee. ( Chalmers, J; MacMahon, S; Neal, B, 2000) |
| "Twelve patients with recurrent renal calculi and renal hypercalciuria were studied using a randomized double-blind cross-over protocol." | 2.68 | Indapamide (Natrilix): the agent of choice in the treatment of recurrent renal calculi associated with idiopathic hypercalciuria. ( Buys, ME; Margolius, LP; Martins, MC; Meyers, AM; Whalley, NA, 1996) |
| "Seventy-five patients with calcium nephrolithiasis and hypercalciuria were randomly assigned to three different therapies: diet and fluid (group A), diet and fluid plus indapamide 2." | 2.67 | Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences. ( Borghi, L; Guerra, A; Meschi, T; Novarini, A, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bogachev, RS | 1 |
| Rfeenkova, VS | 1 |
| Kober, DV | 1 |
| Kraĭtser, AP | 1 |
| Bath, P | 1 |
| Berthet, K | 1 |
| Neal, BC | 1 |
| Chalmers, JP | 1 |
| MacMahon, SW | 1 |
| Bousser, MG | 1 |
| Colman, SA | 1 |
| Woodward, M | 1 |
| Borghi, L | 1 |
| Meschi, T | 1 |
| Guerra, A | 1 |
| Novarini, A | 1 |
| Martins, MC | 1 |
| Meyers, AM | 1 |
| Whalley, NA | 1 |
| Margolius, LP | 1 |
| Buys, ME | 1 |
| Chalmers, J | 1 |
| Neal, B | 1 |
| MacMahon, S | 1 |
| Einecke, D | 1 |
| Masson, C | 1 |
5 trials available for indapamide and Recrudescence
| Article | Year |
|---|---|
Reductions in the risks of recurrent stroke in patients with and without diabetes: the PROGRESS Trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Comorbidity; Diabetes Compl | 2004 |
Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences.
Topics: Adult; Allopurinol; Blood Chemical Analysis; Blood Pressure; Calcium; Female; Follow-Up Studies; Hea | 1993 |
Indapamide (Natrilix): the agent of choice in the treatment of recurrent renal calculi associated with idiopathic hypercalciuria.
Topics: Calcium; Cross-Over Studies; Diuretics; Dose-Response Relationship, Drug; Double-Blind Method; Human | 1996 |
PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. PROGRESS Management Committee.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cerebrovascular Disorders; Diuretics; Double-Blind M | 1998 |
PROGRESS (Perindopril Protection Against Recurrent Stroke Study): regional characteristics of the study population at baseline. PROGRESS Management Committee.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Diuretics; Double-Blind Method; Drug | 2000 |
4 other studies available for indapamide and Recrudescence
| Article | Year |
|---|---|
[Clinical aspects of vaso-and cardioprotection in patients with primary and recurrent myocardial infarction].
Topics: Cardiotonic Agents; Coronary Angiography; Coronary Vessels; Drug Combinations; Endothelium-Dependent | 2014 |
Blood pressure-lowering for secondary prevention of stroke: ACE inhibition is not the key.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bloo | 2003 |
[PROGRESS Study examines transient cerebral ischemia and stroke patients. Future goal: attaining basic blood pressure control].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Double-Blind Meth | 2001 |
[Efficacy of a converting enzyme inhibitor in the prevention of recurrence of stroke].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diuretics; Drug T | 2001 |